Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Cellular and molecular mechanisms in kidney fibrosis
Jeremy S. Duffield
Jeremy S. Duffield
Published June 2, 2014
Citation Information: J Clin Invest. 2014;124(6):2299-2306. https://doi.org/10.1172/JCI72267.
View: Text | PDF
Review Series

Cellular and molecular mechanisms in kidney fibrosis

  • Text
  • PDF
Abstract

Fibrosis is a characteristic feature of all forms of chronic kidney disease. Deposition of pathological matrix in the interstitial space and within the walls of glomerular capillaries as well as the cellular processes resulting in this deposition are increasingly recognized as important factors amplifying kidney injury and accelerating nephron demise. Recent insights into the cellular and molecular mechanisms of fibrogenesis herald the promise of new therapies to slow kidney disease progression. This review focuses on new findings that enhance understanding of cellular and molecular mechanisms of fibrosis, the characteristics of myofibroblasts, their progenitors, and molecular pathways regulating both fibrogenesis and its resolution.

Authors

Jeremy S. Duffield

×

Figure 2

Results of fate-mapping studies of kidney myofibroblast progenitors.

Options: View larger image (or click on image) Download as PowerPoint
Results of fate-mapping studies of kidney myofibroblast progenitors.
OSR...
OSR1+ intermediate mesoderm progenitors give rise to FOXD1+ progenitors and progenitors of the collecting duct (CD), epithelium, and endothelium. This patterning occurs by 9.5 dpc in mouse embryos. FOXD1+ progenitors established by this time self-renew to give rise to stroma and mural cells of the kidney. Potentially, a second population of progenitors expresses P0 in the neural crest, which then migrates to the cortical nephrogenic stroma and contributes to FOXD1+ stromal progenitors at 13.5 dpc. FOXD1 progeny give rise to mural cells and resident fibroblasts. In disease settings, FOXD1-lineage cells become the vast majority of myofibroblasts in models of kidney disease.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts